STOCK TITAN

Acacia Research Reports Second Quarter 2024 Financial Results

Rhea-AI Impact
(Neutral)
Rhea-AI Sentiment
(Neutral)
Tags

Acacia Research (Nasdaq: ACTG) reported robust financial results for Q2 2024.

Total revenue soared by 227% YoY to $25.8 million, driven by the acquisition of operated producing wells in the Western Anadarko Basin. Revenue for the first six months of 2024 reached $50.2 million, up 121% YoY.

However, Acacia recorded a GAAP net loss of $8.4 million for the quarter, or $0.08 per diluted share. Excluding a $0.06 per share expense related to the AIP Matter, the net loss would have been $0.02 per share.

Operating cash flow improved significantly, generating $71 million in the first half of 2024. Book value per share increased to $5.95, or $6.07 excluding the AIP Matter accrual.

Adjusted EBITDA was $4.1 million for Q2 2024. The company continues to focus on free cash flow generation and enhancing book value per share.

Acacia Research (Nasdaq: ACTG) ha riportato risultati finanziari robusti per il secondo trimestre del 2024.

Le entrate totali sono aumentate del 227% rispetto all'anno precedente, raggiungendo i 25,8 milioni di dollari, grazie all'acquisizione di pozzi produttivi operativi nel Western Anadarko Basin. Le entrate dei primi sei mesi del 2024 hanno raggiunto i 50,2 milioni di dollari, con un incremento del 121% su base annua.

Tuttavia, Acacia ha registrato una perdita netta GAAP di 8,4 milioni di dollari per il trimestre, pari a 0,08 dollari per azione diluita. Escludendo una spesa di 0,06 dollari per azione relativa alla questione AIP, la perdita netta sarebbe stata di 0,02 dollari per azione.

Il flusso di cassa operativo è migliorato significativamente, generando 71 milioni di dollari nella prima metà del 2024. Il valore contabile per azione è aumentato a 5,95 dollari, o a 6,07 dollari escludendo l'accantonamento della questione AIP.

L'EBITDA rettificato è stato di 4,1 milioni di dollari per il secondo trimestre del 2024. L'azienda continua a concentrarsi sulla generazione di flusso di cassa libero e sul miglioramento del valore contabile per azione.

Acacia Research (Nasdaq: ACTG) informó resultados financieros sólidos para el segundo trimestre de 2024.

Los ingresos totales se dispararon un 227% interanual hasta alcanzar los 25,8 millones de dólares, impulsados por la adquisición de pozos en producción en el Western Anadarko Basin. Los ingresos durante los primeros seis meses de 2024 alcanzaron los 50,2 millones de dólares, lo que representa un aumento del 121% interanual.

No obstante, Acacia reportó una pérdida neta GAAP de 8,4 millones de dólares para el trimestre, es decir, 0,08 dólares por acción diluida. Excluyendo un gasto de 0,06 dólares por acción relacionado con el asunto de AIP, la pérdida neta habría sido de 0,02 dólares por acción.

El flujo de efectivo operativo mejoró significativamente, generando 71 millones de dólares en la primera mitad de 2024. El valor contable por acción aumentó a 5,95 dólares, o a 6,07 dólares excluyendo el acumulado del asunto AIP.

El EBITDA ajustado fue de 4,1 millones de dólares para el segundo trimestre de 2024. La empresa continúa enfocándose en la generación de flujo de efectivo libre y en mejorar el valor contable por acción.

아카시아 리서치 (Nasdaq: ACTG)는 2024년 2분기 재무 실적을 강력하게 보고했습니다.

총 수익은 전년 대비 227% 증가하여 2,580만 달러에 달했으며, 이는 웨스턴 아나다르코 분지에서 운영 중인 생산 우물의 인수에 힘입은 것입니다. 2024년 상반기 수익은 5,020만 달러에 이르렀으며, 이는 전년 대비 121% 증가한 수치입니다.

그러나 아카시아는 분기 동안 GAAP 순손실로 840만 달러를 기록했으며, 이는 희석 주당 0.08 달러에 해당합니다. AIP 문제와 관련된 주당 0.06 달러의 비용을 제외하면 순손실은 주당 0.02 달러로 줄어들었을 것입니다.

운영 현금 흐름은 크게 개선되어 2024년 상반기에 7,100만 달러를 창출했습니다. 주당 장부 가치는 5.95달러로 증가했으며, AIP 문제의 적립액을 제외하면 6.07달러에 달합니다.

조정된 EBITDA는 2024년 2분기에 410만 달러였습니다. 회사는 자유 현금 흐름 생성과 주당 장부 가치 향상에 계속 집중하고 있습니다.

Acacia Research (Nasdaq: ACTG) a rapporté des résultats financiers solides pour le deuxième trimestre 2024.

Les revenus totaux ont grimpé de 227% d'une année sur l'autre pour atteindre 25,8 millions de dollars, soutenus par l'acquisition de puits de production dans le Western Anadarko Basin. Les revenus pour les six premiers mois de 2024 ont atteint 50,2 millions de dollars, en hausse de 121% par rapport à l'année précédente.

Cependant, Acacia a enregistré une perte nette GAAP de 8,4 millions de dollars pour le trimestre, soit 0,08 dollar par action diluée. En excluant une dépense de 0,06 dollar par action liée à l'affaire AIP, la perte nette aurait été de 0,02 dollar par action.

Le flux de trésorerie d'exploitation s'est considérablement amélioré, générant 71 millions de dollars au cours de la première moitié de 2024. La valeur comptable par action a augmenté à 5,95 dollars, ou 6,07 dollars excluant l'accumulation de l'affaire AIP.

L'EBITDA ajusté s'élevait à 4,1 millions de dollars pour le deuxième trimestre 2024. L'entreprise continue de se concentrer sur la génération de flux de trésorerie libre et l'amélioration de la valeur comptable par action.

Acacia Research (Nasdaq: ACTG) hat für das zweite Quartal 2024 starke Finanzzahlen gemeldet.

Der Gesamterlös stieg gegenüber dem Vorjahr um 227% auf 25,8 Millionen Dollar, was durch die Akquisition von produzierenden Wells im Western Anadarko Basin vorangetrieben wurde. Der Umsatz in den ersten sechs Monaten des Jahres 2024 erreichte 50,2 Millionen Dollar, was einem Anstieg von 121% im Vergleich zum Vorjahr entspricht.

Allerdings verzeichnete Acacia einen GAAP Nettoverlust von 8,4 Millionen Dollar für das Quartal, oder 0,08 Dollar pro verwässerter Aktie. Ohne eine Belastung von 0,06 Dollar pro Aktie, die mit der AIP-Angelegenheit verbunden ist, hätte der Nettoverlust 0,02 Dollar pro Aktie betragen.

Betrieblicher Cashflow verbesserte sich erheblich und erzielte in der ersten Hälfte des Jahres 2024 71 Millionen Dollar. Der Buchwert pro Aktie stieg auf 5,95 Dollar oder 6,07 Dollar ohne Berücksichtigung des Rückstellungsbetrags der AIP-Angelegenheit.

Das bereinigte EBITDA lag im zweiten Quartal 2024 bei 4,1 Millionen Dollar. Das Unternehmen konzentriert sich weiterhin auf die Generierung von Freiem Cashflow und die Steigerung des Buchwerts pro Aktie.

Positive
  • Revenue increased 227% YoY to $25.8 million.
  • Total revenue for the first six months of 2024 grew 121% YoY to $50.2 million.
  • Operating cash flow improved significantly, generating $71 million in the first half of 2024.
  • Book value per share increased to $5.95, or $6.07 excluding the AIP Matter accrual.
  • Adjusted EBITDA of $4.1 million for Q2 2024.
Negative
  • Recorded GAAP net loss of $8.4 million for Q2 2024.
  • GAAP diluted net loss per share was $0.08 for Q2 2024.

Insights

Acacia Research's Q2 2024 results show significant growth, with consolidated revenue up 227% YoY to $25.8 million. The company's strategic acquisition of Revolution Assets through Benchmark subsidiary is driving this growth, contributing $14.2 million in revenue. However, the company still reported a GAAP net loss of $8.4 million, or $0.08 per share.

The book value per share increased to $5.95, up from $5.90 at the end of 2023. Excluding the $12.9 million AIP Matter accrual, it would have been $6.07. This growth in book value, combined with strong operating cash flow of $71 million in H1 2024, indicates improving financial health despite the net loss.

The company's focus on free cash flow generation and book value accretion could be positive for long-term value creation, but investors should monitor the path to profitability closely.

Acacia's acquisition of Revolution Assets marks a significant expansion into the energy sector, adding 140,000 net acres and 470 operated producing wells in the Western Anadarko Basin. This strategic move contributed $14.2 million in revenue for Q2, demonstrating immediate impact.

The energy operations segment is showing promise, with $16 million in revenue for H1 2024. However, investors should note the $82 million in non-recourse debt at Benchmark. The focus on operated producing wells suggests a strategy aimed at stable cash flows, which could provide a buffer against volatile oil prices.

While this diversification is promising, the energy sector's cyclical nature and environmental concerns could pose risks. Acacia's ability to efficiently manage these assets and navigate industry challenges will be important for long-term success in this vertical.

Acacia's IP operations showed remarkable growth, with licensing revenue increasing from $0.4 million in Q2 2023 to $5.3 million in Q2 2024. This 1225% YoY increase suggests a significant improvement in monetizing their IP portfolio.

The company's success in its Life Sciences Portfolio is particularly noteworthy, having generated $564.1 million in proceeds from an initial investment of $301.4 million. This represents an impressive ROI of 87%. The remaining $25.7 million book value in private companies presents further potential upside.

However, the volatility in IP revenue streams and the challenges in consistently monetizing patents mean that investors should view this segment's performance cautiously. The company's ability to maintain this growth trajectory in IP licensing will be important for future performance.

Increased Consolidated Revenue 227% Compared to Q2 2023, Up 121% Compared to the First Six Months of 2023

Significant YoY Revenue and Operating Cash Flow Improvement During Q2 2024

Acacia Remains Focused on Free Cash Flow Generation and Book Value Per Share Accretion

NEW YORK--(BUSINESS WIRE)-- Acacia Research Corporation (Nasdaq: ACTG) (“Acacia” or the “Company”) today reported financial results for the three and six months ended June 30, 2024. The Company is also releasing a new Corporate Overview Presentation and a Q2 2024 Earnings Presentation, both of which are being posted today on its website at www.acaciares.com under Events & Presentations.

Martin (“MJ”) D. McNulty, Jr., Chief Executive Officer, stated, “Acacia delivered strong financial and operating results in the second quarter. The Company’s efforts to build excellent businesses are paying off as our second quarter results highlight the evolution, strength and trajectory of the Company’s core technology, energy and industrials verticals. Acacia generated $25.8 million in consolidated revenue, up by 227% compared to the second quarter last year, driven by the completion of our transformative acquisition of operated producing wells in the Western Anadarko Basin through our Benchmark subsidiary.

The Company also delivered significant improvements in year over year revenue and operating cash flow in the second quarter. With disciplined capital allocation and a commitment to operating and financial excellence, the Company increased its total revenues 121% to $50.2 million for the first six months of 2024 compared to the first six months of 2023 and grew the Company’s book value per share by approximately 3% and approximately 2% compared to the book value at December 31, 2023 and March 31, 2024, respectively, excluding an accrual related to the AIP matter.

Looking ahead, we will remain focused on free cash flow generation and book value per share accretion which we believe will deliver stock price growth and generate shareholder value.”

Key Business Highlights

  • Recorded book value per share at June 30, 2024 of $5.95 compared to $5.90 per share at December 31, 2023. Excluding the impact of the additional accrual of $12.9 million related to the AIP Matter (as defined below and which has now been settled), book value per share at June 30, 2024 would have been $6.07 per share.
  • Generated $25.8 million in consolidated revenue for the quarter, including $5.3 million in license fee revenue from the Company’s intellectual property operations, up 227% compared to $7.9 million in revenue in the second quarter of 2023.
  • Recorded a GAAP net loss of $8.4 million, or $0.08 diluted net loss per share, for the second quarter and a GAAP net loss of $8.6 million, or $0.09 diluted net loss per share for the first half of 2024. Excluding the additional expense described above related to the AIP Matter, which represented $0.06 per share, diluted net loss per share for the second quarter of 2024 would have been $0.02.
  • Generated $4.1 million and $10.4 million of adjusted EBITDA1 in the second quarter and first half of 2024, respectively.
  • Generated $71.0 million in operating cash flow in the first half of 2024.
  • On April 17, 2024 Benchmark completed the acquisition of certain upstream assets and related facilities in Texas and Oklahoma from a private seller, expanding Benchmark’s portfolio by approximately 140,000 net acres and adding approximately 470 operated producing wells in the prolific Western Anadarko Basin throughout the Texas Panhandle and Western Oklahoma (the “Revolution Assets”). Acacia’s second quarter 2024 financials reflect the contributions from the Benchmark acquisition.
  • Benchmark generated approximately $14.2 million in revenue in the second quarter, which includes revenue from the Revolution Assets.

1Adjusted EBITDA is a non-GAAP financial measure. For the definition of this measure and a reconciliation of this measure to net loss, the most directly comparable GAAP financial measure, see the accompanying supplemental information table.

Second Quarter 2024 Financial Highlights

(In millions, except per share data)

 

Three Months Ended June 30,

 

Six Months Ended June 30,

 

 

2024

 

 

 

2023

 

 

 

2024

 

 

 

2023

 

 

(unaudited)

 

(unaudited)

Intellectual property operations

$

5.3

 

 

$

0.4

 

 

$

19.0

 

 

$

4.6

 

Industrial operations

 

6.3

 

 

 

7.5

 

 

 

15.2

 

 

 

18.1

 

Energy operations

 

14.2

 

 

 

 

 

 

16.0

 

 

 

 

Total revenues

$

25.8

 

 

$

7.9

 

 

$

50.2

 

 

$

22.7

 

Operating loss

$

(4.8

)

 

$

(12.5

)

 

$

(6.8

)

 

$

(21.9

)

Unrealized (losses) gains1

$

(4.7

)

 

$

6.6

 

 

$

(31.4

)

 

$

10.0

 

Realized gains (losses)

$

 

 

$

(8.0

)

 

$

28.9

 

 

$

(9.4

)

Legal liability fee

$

(6.6

)

 

$

 

 

$

(12.9

)

 

$

 

Non-cash derivative liability (losses) gains2

$

 

 

$

(9.9

)

 

$

 

 

$

6.7

 

GAAP Net loss

$

(8.4

)

 

$

(18.8

)

 

$

(8.6

)

 

$

(9.3

)

GAAP Diluted net loss per share

$

(0.08

)

 

$

(0.36

)

 

$

(0.09

)

 

$

(0.26

)

 

 

 

 

 

 

 

 

1 Unrealized gains and (losses) are related to the change in fair value of equity securities as of the end of the reported period and for the six months ended June 30, 2024 the reversal of the previously recorded unrealized gain related to our

Arix Bioscience Plc. position for a realized gain.

2 The non-cash derivative liability gains and (losses) are related to the change in fair value of Acacia’s Series A and B warrants and embedded derivatives and gains and (losses) from the exercise of warrants.

Second Quarter 2024 Financial Summary:

  • Total revenues were $25.8 million, up 227% compared to $7.9 million in the same quarter last year.
    • The Intellectual Property business generated $5.3 million in licensing and other revenue during the quarter, compared to $0.4 million in the same quarter last year.
    • Printronix generated $6.3 million in revenue during the quarter, compared to $7.5 million in the same quarter last year. The decrease in revenue was primarily due to a decrease in printer sales.
    • Benchmark generated $14.2 million in revenue in the quarter. As the Company’s initial investment in Benchmark closed on November 13, 2023, there is no comparable revenue in the same quarter last year.
  • General and administrative (G&A) expenses were $10.0 million, compared to $9.4 million in the same quarter of last year. The increase was primarily due to an increase in G&A due to the addition of the new energy segment operations partially offset by a decrease in parent legal fees and a decrease in G&A from Printronix.
  • The Company recorded an operating loss of $4.8 million, down 62% compared to a loss of $12.5 million in the same quarter of last year primarily due to higher revenues generated.
    • Printronix contributed $0.2 million in operating loss which included $0.7 million of non-cash depreciation and amortization expenses.
    • Benchmark contributed $3.2 million in operating income, which included $3.5 million of non-cash depreciation, depletion and amortization expenses, and does not reflect $0.1 million of realized derivatives gain. Such income includes revenue from the Revolution Assets.
    • The second quarter included $0.8 million in non-recurring parent general and administrative charges.
  • On August 2, 2024, Acacia settled a dispute involving former executives of the Company regarding a profit interest in AIP Operation LLC (the “AIP Matter”) that had been granted to those former executives at the direction of prior management and the Board of Directors at that time. The settlement resulted in a $14.5 million accrual as of June 30, 2024 and will result in a $14.5 million payment by Acacia in the third quarter of 2024. Accordingly, for the six months ended June 30, 2024 other income (expense) includes an aggregate additional expense of $12.9 million, or $0.13 per share, which is incremental to amounts expensed in prior periods.
  • The Company recorded GAAP net loss of $8.4 million, or $0.08 diluted net loss per share, compared to GAAP net loss of $18.8 million, or $0.36 diluted net loss per share, in the second quarter of last year.
    • Net loss included $4.7 million in unrealized loss related to the fair value of equity securities at June 30, 2024.
    • Excluding the impact of the additional expense relating to the AIP Matter, which represented $0.06 per share, Acacia’s loss per share for the second quarter of 2024 would be $0.02.

Life Sciences Portfolio

Acacia has generated $564.1 million in proceeds from sales and royalties of the Life Sciences Portfolio, which was purchased for an aggregate price of $301.4 million in 2020. At the end of the second quarter, Acacia’s remaining positions in the Life Sciences Portfolio represented $25.7 million in book value:

  • Acacia holds interests in three private companies, valued at an aggregate of $25.7 million, net of non-controlling interests, including an approximately 26% interest in Viamet Pharmaceuticals, Inc., an approximately 18% interest in AMO Pharma, Ltd., and an approximately 4% interest in NovaBiotics Ltd. Values are based on cost or equity accounting.

Balance Sheet and Capital Structure

  • Cash, cash equivalents and equity investments measured at fair value totaled $405.2 million at June 30, 2024 compared to $403.2 million at December 31, 2023. The increase in cash was primarily due to timing of payments received from licensees, offset by $59.9 million paid to acquire the Revolution Assets.
  • Equity securities without readily determinable fair value totaled $5.8 million at June 30, 2024, unchanged from December 31, 2023.
  • Investment securities representing equity method investments totaled $19.9 million at June 30, 2024 (net of noncontrolling interests), unchanged from December 31, 2023. Acacia owns 64% of MalinJ1, which results in a 26% indirect ownership stake in Viamet Pharmaceuticals, Inc. for Acacia.
  • The parent company’s total indebtedness was zero at June 30, 2024. On a consolidated basis, Acacia’s total indebtedness was $82.0 million in non-recourse debt at Benchmark as of June 30, 2024.

Book Value as of June 30, 2024

At June 30, 2024, Acacia’s book value was $596.7 million and there were 100.4 million shares of common stock outstanding, for a book value per share of $5.95. Excluding the impact of the additional accrual of $12.9 million related to the AIP Matter, the Company’s book value per share at June 30, 2024 would have been $6.07 per share.

Investor Conference Call

The Company will host a conference call today, August 8, 2024 at 4:30 p.m. Eastern Time (1:30 p.m. Pacific Time). To access the live call, please dial 800-715-9871 (U.S. and Canada) or 646-307-1963 (international) and if requested, reference the access code “Acacia Research.” The conference call will also be simultaneously webcasted on the investor relations section of the Company’s website at http://www.acaciaresearch.com under Events & Presentations. Following the conclusion of the live call, a replay of the webcast will be available on the Company's website for at least 30 days.

About the Company

Acacia is a publicly traded (Nasdaq: ACTG) company that is focused on acquiring and operating attractive businesses across the mature technology, energy, and industrial/manufacturing sectors where it believes it can leverage its expertise, significant capital base, and deep industry relationships to drive value. Acacia evaluates opportunities based on the attractiveness of the underlying cash flows, without regard to a specific investment horizon. Acacia operates its businesses based on three key principles of people, process and performance and has built a management team with demonstrated expertise in research, transactions and execution, and operations and management. Additional information about Acacia and its subsidiaries is available at www.acaciaresearch.com.

Safe Harbor Statement

This news release contains forward-looking statements within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995. These statements are based upon the Company’s current expectations and speak only as of the date hereof. This news release attempts to identify forward-looking statements by using words such as “anticipate,” “believe,” “could,” “expect,” “intend,” “may,” “plan,” “potential,” “predict,” “project,” “seek,” “should,” “will,” or other forms of these words or similar words or expressions or the negative thereof, although not all forward-looking statements contain these terms. The Company’s actual results may differ materially and adversely from those expressed or implied in any forward-looking statements as a result of various factors and uncertainties, including the Company’s ability to successfully identify and complete strategic acquisitions of businesses, divisions, and/or assets, the performance of businesses, divisions, and/or assets the Company acquires, changes to the Company’s relationship and arrangements with Starboard Value LP, Benchmark’s ability to execute on its business and hedging strategy, risks related to price and other fluctuations in the oil and gas market, inflationary pressures, supply chain disruptions or labor shortages, Benchmark’s ability to replace reserves and efficiently develop current reserves, risks, operational hazards, unforeseen interruptions and other difficulties involved in the production of oil and natural gas, the impact of any seismic events, environmental liability risk, regulatory changes related to the oil and gas industry, the ability to successfully develop licensing programs and attract new business, changes in demand for current and future intellectual property rights, legislative, regulatory and competitive developments addressing licensing and enforcement of patents and/or intellectual property in general, the decrease in demand for Printronix' products, general economic conditions, and the success of the Company’s investments. The Company’s Annual Report on Form 10-K, and other SEC filings discuss these and other important risks and uncertainties that may materially affect the Company’s business, results of operations and financial condition. In addition, actual results may differ materially as a result of additional risks and uncertainties of which the Company is currently unaware or which the Company does not currently view as material. Except as otherwise required by applicable law, the Company undertakes no obligation to revise or update publicly any forward-looking statements for any reason.

The results achieved by the Company in prior periods are not necessarily indicative of the results to be achieved by us in any subsequent periods. It is currently anticipated that the Company’s financial results will vary, and may vary significantly, from quarter to quarter.

 

ACACIA RESEARCH CORPORATION
CONDENSED CONSOLIDATED BALANCE SHEETS
(In thousands, except share and per share data)

 
 

 

June 30, 2024

 

December 31, 2023

 

(Unaudited)

 

 

ASSETS

 

 

 

Current assets:

 

 

 

Cash and cash equivalents

$

386,988

 

 

$

340,091

 

Equity securities

 

18,174

 

 

 

63,068

 

Equity securities without readily determinable fair value

 

5,816

 

 

 

5,816

 

Equity method investments

 

30,934

 

 

 

30,934

 

Accounts receivable, net

 

18,772

 

 

 

80,555

 

Inventories

 

12,289

 

 

 

10,921

 

Prepaid expenses and other current assets

 

20,961

 

 

 

23,127

 

Total current assets

 

493,934

 

 

 

554,512

 

 

 

 

 

Property, plant and equipment, net

 

2,315

 

 

 

2,356

 

Oil and natural gas properties, net

 

192,587

 

 

 

25,117

 

Goodwill

 

8,990

 

 

 

8,990

 

Other intangible assets, net

 

36,017

 

 

 

33,556

 

Operating lease, right-of-use assets

 

1,639

 

 

 

1,872

 

Deferred income tax assets, net

 

13,854

 

 

 

2,915

 

Other non-current assets

 

4,257

 

 

 

4,227

 

Total assets

$

753,593

 

 

$

633,545

 

 

 

 

 

LIABILITIES AND STOCKHOLDERS' EQUITY

 

 

 

Current liabilities:

 

 

 

Accounts payable

$

3,191

 

 

$

3,261

 

Accrued expenses and other current liabilities

 

15,207

 

 

 

8,405

 

Accrued compensation

 

3,983

 

 

 

4,207

 

Asset retirement obligation

 

1,543

 

 

 

 

Royalties and contingent legal fees payable

 

4,869

 

 

 

10,786

 

Deferred revenue

 

911

 

 

 

977

 

Accrued loss contingency

 

14,500

 

 

 

 

Total current liabilities

 

44,204

 

 

 

27,636

 

 

 

 

 

Asset retirement obligation

 

27,718

 

 

 

 

Long-term lease liabilities

 

1,447

 

 

 

1,736

 

Revolving credit facility

 

82,000

 

 

 

10,525

 

Other long-term liabilities

 

1,479

 

 

 

4,039

 

Total liabilities

 

156,848

 

 

 

43,936

 

 

 

 

 

Commitments and contingencies

 

 

 

 

 

 

 

 

 

 

 

Stockholders' equity:

 

 

 

Preferred stock, par value $0.001 per share; 10,000,000 shares authorized; no shares issued or outstanding

 

 

 

 

 

Common stock, par value $0.001 per share; 300,000,000 shares authorized; 100,375,459 and 99,895,473 shares issued and outstanding as of June 30, 2024 and December 31, 2023, respectively

 

100

 

 

 

100

 

Treasury stock, at cost, 16,183,703 shares as of June 30, 2024 and December 31, 2023

 

(98,258

)

 

 

(98,258

)

Additional paid-in capital

 

907,215

 

 

 

906,153

 

Accumulated deficit

 

(248,361

)

 

 

(239,729

)

Total Acacia Research Corporation stockholders' equity

 

560,696

 

 

 

568,266

 

 

 

 

 

Noncontrolling interests

 

36,049

 

 

 

21,343

 

 

 

 

 

Total stockholders' equity

 

596,745

 

 

 

589,609

 

 

 

 

 

Total liabilities and stockholders' equity

$

753,593

 

 

$

633,545

 

 

ACACIA RESEARCH CORPORATION
UNAUDITED CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS
(In thousands, except share and per share data)

 
 

 

Three Months Ended June 30,

 

Six Months Ended June 30,

 

 

2024

 

 

 

2023

 

 

 

2024

 

 

 

2023

 

 

 

 

 

 

 

 

 

Revenues:

 

 

 

 

 

 

 

Intellectual property operations

$

5,333

 

 

$

394

 

 

$

18,956

 

 

$

4,570

 

Industrial operations

 

6,335

 

 

 

7,510

 

 

 

15,176

 

 

 

18,137

 

Energy operations

 

14,170

 

 

 

 

 

 

16,026

 

 

 

 

Total revenues

 

25,838

 

 

 

7,904

 

 

 

50,158

 

 

 

22,707

 

 

 

 

 

 

 

 

 

Costs and expenses:

 

 

 

 

 

 

 

Cost of revenues - intellectual property operations

 

5,765

 

 

 

5,010

 

 

 

12,766

 

 

 

9,748

 

Cost of revenues - industrial operations

 

3,277

 

 

 

3,933

 

 

 

7,326

 

 

 

9,153

 

Cost of production - energy operations

 

10,038

 

 

 

 

 

 

11,353

 

 

 

 

Engineering and development expenses - industrial operations

 

178

 

 

 

205

 

 

 

312

 

 

 

421

 

Sales and marketing expenses - industrial operations

 

1,387

 

 

 

1,859

 

 

 

2,942

 

 

 

3,772

 

General and administrative expenses

 

9,951

 

 

 

9,426

 

 

 

22,304

 

 

 

21,466

 

Total costs and expenses

 

30,596

 

 

 

20,433

 

 

 

57,003

 

 

 

44,560

 

Operating loss

 

(4,758

)

 

 

(12,529

)

 

 

(6,845

)

 

 

(21,853

)

 

 

 

 

 

 

 

 

Other (expense) income:

 

 

 

 

 

 

 

Equity securities investments:

 

 

 

 

 

 

 

Change in fair value of equity securities

 

(4,744

)

 

 

6,617

 

 

 

(31,445

)

 

 

9,960

 

Gain (loss) on sale of equity securities

 

 

 

 

(7,999

)

 

 

28,861

 

 

 

(9,360

)

Net realized and unrealized (loss) gain

 

(4,744

)

 

 

(1,382

)

 

 

(2,584

)

 

 

600

 

Legal liability fee

 

(6,613

)

 

 

 

 

 

(12,856

)

 

 

 

Change in fair value of the Series B warrants and embedded derivatives

 

 

 

 

(9,935

)

 

 

 

 

 

6,716

 

(Loss) gain on foreign currency exchange

 

(70

)

 

 

15

 

 

 

(88

)

 

 

95

 

Interest expense on Senior Secured Notes

 

 

 

 

(900

)

 

 

 

 

 

(1,800

)

Interest income and other, net

 

295

 

 

 

4,307

 

 

 

5,185

 

 

 

7,748

 

Total other (expense) income

 

(11,132

)

 

 

(7,895

)

 

 

(10,343

)

 

 

13,359

 

 

 

 

 

 

 

 

 

Loss before income taxes

 

(15,890

)

 

 

(20,424

)

 

 

(17,188

)

 

 

(8,494

)

 

 

 

 

 

 

 

 

Income tax benefit (expense)

 

7,061

 

 

 

1,645

 

 

 

8,170

 

 

 

(838

)

 

 

 

 

 

 

 

 

Net loss including noncontrolling interests in subsidiaries

 

(8,829

)

 

 

(18,779

)

 

 

(9,018

)

 

 

(9,332

)

 

 

 

 

 

 

 

 

Net loss attributable to noncontrolling interests in subsidiaries

 

383

 

 

 

 

 

 

386

 

 

 

 

 

 

 

 

 

 

 

 

Net loss attributable to Acacia Research Corporation

$

(8,446

)

 

$

(18,779

)

 

$

(8,632

)

 

$

(9,332

)

 

 

 

 

 

 

 

 

Loss per share:

 

 

 

 

 

 

 

Net loss attributable to common stockholders - Basic

$

(8,446

)

 

$

(21,155

)

 

$

(8,632

)

 

$

(13,962

)

Weighted average number of shares outstanding - Basic

 

100,079,803

 

 

 

58,408,711

 

 

 

99,912,854

 

 

 

53,219,152

 

Basic net loss per common share

$

(0.08

)

 

$

(0.36

)

 

$

(0.09

)

 

$

(0.26

)

Net loss attributable to common stockholders - Diluted

$

(8,446

)

 

$

(21,155

)

 

$

(8,632

)

 

$

(13,962

)

Weighted average number of shares outstanding - Diluted

 

100,079,803

 

 

 

58,408,711

 

 

 

99,912,854

 

 

 

53,219,152

 

Diluted net loss per common share

$

(0.08

)

 

$

(0.36

)

 

$

(0.09

)

 

$

(0.26

)

 

ACACIA RESEARCH CORPORATION - SUPPLEMENTAL INFORMATION
NON-GAAP FINANCIAL MEASURE

This earnings release includes adjusted EBITDA, which is a supplemental non-GAAP financial measure used by management and external users of the Company’s consolidated financial statements. GAAP refers to generally accepted accounting principles in the United States. A non-GAAP financial measure is a numerical measure of historical or future performance, financial position or cash flow that includes or excludes amounts that are excluded or included, respectively, in the most directly comparable measure calculated and presented in accordance with GAAP in the Company’s financial statements.

Adjusted EBITDA is defined as net income / (loss) before net income / (loss) attributable to noncontrolling interests, income tax (benefit) / expense, interest income and other, net, loss / (gain) on foreign currency exchange, net realized and unrealized loss / (gain) on investments, legal liability fee, depreciation, depletion and amortization, stock-based compensation, realized hedge gain / (loss), transaction-related costs, and costs related to certain legacy items. We are providing Adjusted EBITDA, a non-GAAP financial measure, because management believes the metric provides investors with useful supplemental information in comparing the operating results across reporting periods by excluding items that are not considered indicative of core operating performance. This measure is not intended to replace the presentation of financial results in accordance with GAAP and may be different from or otherwise inconsistent with similar non-GAAP financial measures used by other companies. The presentation of this non-GAAP financial measures supplements other metrics the Company uses to internally evaluate its subsidiary businesses and facilitate the comparison of past and present operating performance. This measure should not be considered in isolation or as a substitute for measures calculated and presented in accordance with GAAP.

The following table provides a reconciliation of adjusted EBITDA to net loss, the most directly comparable GAAP measure.

 

Three Months Ended
March 31,

 

Three Months Ended
June 30,

 

Six Months Ended
June 30,

Adjusted EBITDA

 

2024

 

 

 

2024

 

 

 

2024

 

 

(In thousands)

 

(Unaudited)

GAAP Net Loss

$

(186

)

 

$

(8,446

)

 

$

(8,632

)

Net Loss Attributable to Noncontrolling Interests

 

(3

)

 

 

(383

)

 

 

(386

)

Income Tax Benefit

 

(1,109

)

 

 

(7,061

)

 

 

(8,170

)

Interest Income and Other, Net

 

(4,890

)

 

 

(295

)

 

 

(5,185

)

Loss on Foreign Currency Exchange

 

18

 

 

 

70

 

 

 

88

 

Net Realized and Unrealized (Gain) / Loss on Investments

 

(2,160

)

 

 

4,744

 

 

 

2,584

 

Legal liability fee

 

6,243

 

 

 

6,613

 

 

 

12,856

 

GAAP Operating Loss

$

(2,087

)

 

$

(4,758

)

 

$

(6,845

)

Depreciation, Depletion & Amortization

 

4,568

 

 

 

7,407

 

 

 

11,973

 

Stock-Based Compensation

 

858

 

 

 

891

 

 

 

1,749

 

Realized Hedge Gain

 

800

 

 

 

113

 

 

 

913

 

Transaction-Related Costs

 

 

 

 

222

 

 

 

222

 

Legal Costs - Legacy Management

 

2,193

 

 

 

216

 

 

 

2,408

 

Adjusted EBITDA

$

6,332

 

 

$

4,091

 

 

$

10,420

 

 

Investor Contact:

Gagnier Communications

ir@acaciares.com

Source: Acacia Research Corporation

FAQ

What were Acacia Research's Q2 2024 earnings results?

Acacia reported a GAAP net loss of $8.4 million, or $0.08 diluted net loss per share.

How much did Acacia Research's revenue grow in Q2 2024?

Revenue grew by 227% YoY to $25.8 million.

What was Acacia Research's total revenue for the first six months of 2024?

Total revenue for the first six months was $50.2 million, up 121% YoY.

How did Acacia Research's book value per share change in Q2 2024?

Book value per share increased to $5.95, or $6.07 excluding the AIP Matter accrual.

What was Acacia Research's operating cash flow in the first half of 2024?

Operating cash flow improved significantly, generating $71 million in the first half of 2024.

Acacia Research Corporation

NASDAQ:ACTG

ACTG Rankings

ACTG Latest News

ACTG Stock Data

440.15M
100.38M
1.76%
86.77%
1.31%
Business Equipment & Supplies
Patent Owners & Lessors
Link
United States of America
NEW YORK